MarketPeel
Insider Trading Intelligence
Pricing
…
SN

Sukumar Nagendran

SLDB
DIRECTOR · SOLID BIOSCIENCES INC. · CIK 0001665124
FILING MIX · LIFETIME65%/35%
BUYS
30
SELLS
16
TOTAL VALUE
$5.82M
COMPANIES
2
ACTIVE SINCE
Jun 2020
HOLDINGS NOW
1,213,910
AVG SELL PX
$4.27
TRADE KIND
SHOWING 46 / 46
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
10 backtested trades · 8 horizons · 21 pending
Forward-return performance of every backtestable P/S trade by Sukumar Nagendran, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d10+70.00%+6.89%+0.78%+6.11%+1.50%—
14d10+40.00%+9.59%+0.85%+8.74%-0.11%—
30d10+40.00%+12.79%+1.52%+11.27%+3.76%—
60d10+30.00%+6.43%+1.41%+5.03%-2.12%—
90d10(1 pending)+33.33%+36.75%+1.83%+34.92%+33.63%—
180d10(4 pending)+16.67%+32.75%+2.50%+34.13%+44.69%—
1y10(8 pending)+50.00%+132.41%+11.81%+120.61%+120.61%—
2y10(8 pending)+50.00%+94.83%+29.69%+65.14%+65.14%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
SLDB · 77,500 shares · as of Jun 10, 2026
019,37538,75058,12577,500202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 30 buys / 16 sellsCOVERAGE · 25 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
SLDB
SOLID BIOSCIENCES INC.
PURCHASEGRANT
Stock grant
77,500——77,500Jun 10, 2026Jun 11, 2026 ↗View →
TSHA
TAYSHA GENE THERAPIES, INC.
PURCHASE
President and Head of R&D
19,021$1.71$32.5K1,336,410Apr 10, 2026Apr 13, 2026 ↗View →
TSHA
TAYSHA GENE THERAPIES, INC.
SALE
President and Head of R&D
19,021——455,920Apr 10, 2026Apr 13, 2026 ↗View →
TSHA
TAYSHA GENE THERAPIES, INC.
SALE10b5-1
10b5-1 plan
200,000$4.46$892.0K1,136,410Apr 10, 2026Apr 13, 2026 ↗View →
TSHA
TAYSHA GENE THERAPIES, INC.
SALE
President and Head of R&D
26,918$4.61$124.1K1,317,389Jan 26, 2026Jan 27, 2026 ↗View →
TSHA
TAYSHA GENE THERAPIES, INC.
SALE
President and Head of R&D
89,132$4.75$423.4K1,344,307Jan 23, 2026Jan 27, 2026 ↗View →
TSHA
TAYSHA GENE THERAPIES, INC.
PURCHASEGRANT
Stock grant
274,000——274,000Jan 12, 2026Jan 14, 2026 ↗View →
TSHA
TAYSHA GENE THERAPIES, INC.
PURCHASE
President and Head of R&D
111,324$0.70$77.8K1,117,763Jan 12, 2026Jan 14, 2026 ↗View →
TSHA
TAYSHA GENE THERAPIES, INC.
SALE
President and Head of R&D
88,676——474,941Jan 12, 2026Jan 14, 2026 ↗View →
TSHA
TAYSHA GENE THERAPIES, INC.
PURCHASE
President and Head of R&D
88,676$1.71$151.6K1,206,439Jan 12, 2026Jan 14, 2026 ↗View →
TSHA
TAYSHA GENE THERAPIES, INC.
SALE
President and Head of R&D
111,324——111,359Jan 12, 2026Jan 14, 2026 ↗View →
TSHA
TAYSHA GENE THERAPIES, INC.
SALE10b5-1
10b5-1 plan
200,000$4.71$942.0K1,006,439Jan 12, 2026Jan 14, 2026 ↗View →
TSHA
TAYSHA GENE THERAPIES, INC.
PURCHASEGRANT
Stock grant
427,000——1,433,439Jan 12, 2026Jan 14, 2026 ↗View →
TSHA
TAYSHA GENE THERAPIES, INC.
PURCHASE
President and Head of R&D
260,047$1.71$444.7K1,266,486Dec 1, 2025Dec 1, 2025 ↗View →
TSHA
TAYSHA GENE THERAPIES, INC.
SALE
President and Head of R&D
260,047$4.51$1.17M1,006,439Dec 1, 2025Dec 1, 2025 ↗View →
TSHA
TAYSHA GENE THERAPIES, INC.
SALE
President and Head of R&D
260,047——563,617Dec 1, 2025Dec 1, 2025 ↗View →
TSHA
TAYSHA GENE THERAPIES, INC.
SALE
President and Head of R&D
39,953——823,664Nov 28, 2025Dec 1, 2025 ↗View →
TSHA
TAYSHA GENE THERAPIES, INC.
SALE
President and Head of R&D
70,172——222,683Nov 28, 2025Dec 1, 2025 ↗View →
TSHA
TAYSHA GENE THERAPIES, INC.
PURCHASE
President and Head of R&D
39,953$1.71$68.3K1,116,564Nov 28, 2025Dec 1, 2025 ↗View →
TSHA
TAYSHA GENE THERAPIES, INC.
PURCHASE
President and Head of R&D
70,172$0.70$49.0K1,076,611Nov 28, 2025Dec 1, 2025 ↗View →
TSHA
TAYSHA GENE THERAPIES, INC.
SALE
President and Head of R&D
110,125$4.75$523.1K1,006,439Nov 28, 2025Dec 1, 2025 ↗View →
TSHA
TAYSHA GENE THERAPIES, INC.
PURCHASE
President and Head of R&D
41,150$0.70$28.8K1,206,439Sep 10, 2025Sep 12, 2025 ↗View →
TSHA
TAYSHA GENE THERAPIES, INC.
SALE
President and Head of R&D
41,150——292,855Sep 10, 2025Sep 12, 2025 ↗View →
TSHA
TAYSHA GENE THERAPIES, INC.
SALE10b5-1
10b5-1 plan
200,000$3.23$646.0K1,006,439Sep 10, 2025Sep 12, 2025 ↗View →
TSHA
TAYSHA GENE THERAPIES, INC.
SALE
President and Head of R&D
57,054$2.85$162.6K1,165,289Aug 21, 2025Aug 22, 2025 ↗View →
SLDB
SOLID BIOSCIENCES INC.
PURCHASEGRANT
Stock grant
77,500——77,500Jun 12, 2025Jun 13, 2025 ↗View →
TSHA
TAYSHA GENE THERAPIES, INC.
PURCHASEGRANT
Stock grant
324,500——1,222,343Jan 2, 2025Jan 3, 2025 ↗View →
TSHA
TAYSHA GENE THERAPIES, INC.
PURCHASEGRANT
Stock grant
324,500——324,500Jan 2, 2025Jan 3, 2025 ↗View →
SLDB
SOLID BIOSCIENCES INC.
PURCHASEGRANT
Stock grant
34,400——34,400Jun 11, 2024Jun 13, 2024 ↗View →
TSHA
TAYSHA GENE THERAPIES, INC.
PURCHASEGRANT
Stock grant
863,617——897,843Jan 2, 2024Jan 4, 2024 ↗View →
TSHA
TAYSHA GENE THERAPIES, INC.
PURCHASEGRANT
Stock grant
863,617——863,617Jan 2, 2024Jan 4, 2024 ↗View →
TSHA
TAYSHA GENE THERAPIES, INC.
PURCHASEGRANT
Stock grant
334,005——334,005Dec 14, 2023Dec 18, 2023 ↗View →
SLDB
SOLID BIOSCIENCES INC.
PURCHASEGRANT
Stock grant
9,650——9,650Jun 6, 2023Jun 8, 2023 ↗View →
TSHA
TAYSHA GENE THERAPIES, INC.
PURCHASE
President and Head of R&D
5,000$0.68$3.4K34,226May 16, 2023May 18, 2023 ↗View →
TSHA
TAYSHA GENE THERAPIES, INC.
PURCHASEGRANT
Stock grant
790,093——790,093Dec 30, 2022Jan 4, 2023 ↗View →
SLDB
SOLID BIOSCIENCES INC.
PURCHASEGRANT
Stock grant
9,650——9,650Dec 13, 2022Dec 15, 2022 ↗View →
TSHA
TAYSHA GENE THERAPIES, INC.
PURCHASEGRANT
Stock grant
15,500——15,500Jun 17, 2022Jun 22, 2022 ↗View →
SLDB
SOLID BIOSCIENCES INC.
PURCHASEGRANT
Stock grant
51,000——51,000Jun 7, 2022Jun 9, 2022 ↗View →
TSHA
TAYSHA GENE THERAPIES, INC.
PURCHASE
10,000$8.01$80.1K29,226Feb 2, 2022Feb 3, 2022 ↗View →
TSHA
TAYSHA GENE THERAPIES, INC.
PURCHASEGRANT
Stock grant
15,500——15,500Jun 17, 2021Jun 21, 2021 ↗View →
SLDB
SOLID BIOSCIENCES INC.
PURCHASEGRANT
Stock grant
30,000——30,000Jun 16, 2021Jun 21, 2021 ↗View →
TSHA
TAYSHA GENE THERAPIES, INC.
SALE
17,647——0Sep 28, 2020Sep 30, 2020 ↗View →
TSHA
TAYSHA GENE THERAPIES, INC.
PURCHASE
19,226——19,226Sep 28, 2020Sep 30, 2020 ↗View →
TSHA
TAYSHA GENE THERAPIES, INC.
PURCHASEGRANT
Stock grant
31,000——31,000Sep 23, 2020Sep 25, 2020 ↗View →
SLDB
SOLID BIOSCIENCES INC.
PURCHASEGRANT
Stock grant
10,000——10,000Jun 16, 2020Jun 18, 2020 ↗View →
SLDB
SOLID BIOSCIENCES INC.
PURCHASEGRANT
Stock grant
30,000——30,000Jun 16, 2020Jun 18, 2020 ↗View →
Other insiders · SLDB
Loading peer insiders…
About this filer
CIK 0001665124
ROLE
Director
PRIMARY
SLDB
COMPANIES
2
ACTIVE SINCE
Jun 2020
MARKETPEEL · /INSIDER/0001665124DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback